ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis

Du, Tian-Qi; Liu, Ruifeng; Zhang, Qiuning*; Luo, Hongtao; Liu, Zhiqiang; Sun, Shilong; Wang, Xiaohu*兰州大学; 中国科学院研究生院; 1
Biomolecules2022-11DOI: 10.3390/biom12111617
1被引13阅读
引用收藏
分享

摘要

Prostate cancer (PCa) is a type of potentially fatal malignant tumor. Immunotherapy has shown a lot of potential for various types of solid tumors, but the benefits have been less impressive in PCa. Enhancer of zeste homolog 2 (EZH2) is one of the three core subunits of the polycomb repressive complex 2 that has histone methyltransferase activity, and the immune effects of EZH2 in PCa are still unclear. The purpose of this study was to explore the potential of EZH2 as a prognostic factor and an immune therapeutic biomarker for PCa, as well as the expression pattern and biological functions. All analyses in this study were based on publicly available databases, mainly containing Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), UCSCXenaShiny, and TISIDB. We performed differential expression analysis, developed a prognostic model, and explored potential associations between EZH2 and DNA methylation modifications, tumor microenvironment (TME), immune-related genes, tumor mutation burden (TMB), tumor neoantigen burden (TNB), and representative mismatch repair (MMR) genes. We also investigated the molecular and immunological characterizations of EZH2. Finally, we predicted immunotherapeutic responses based on EZH2 expression levels. We found that EZH2 was highly expressed in PCa, was associated with a poor prognosis, and may serve as an independent prognostic factor. EZH2 expression in PCa was associated with DNA methylation modifications, TME, immune-related genes, TMB, TNB, and MMR. By gene set enrichment analysis and gene set variation analysis, we found that multiple functions and pathways related to tumorigenesis, progression, and immune activation were enriched. Finally, we inferred that immunotherapy may be more effective for PCa patients with low EZH2 expression. In conclusion, our study showed that EZH2 could be a potentially efficient predictor of prognosis and immune response in PCa patients.

学科与关键词

关键词
prostate cancerEZH2bioinformaticsprognosisimmunotherapy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Biomolecules
发表日期
2022-11
卷期
第 12 卷, 第 11 期
页码
1617
DOI
10.3390/biom12111617
期刊等级
3区
成果收录
SCIE
资助标注
Science and Technology Plan Project of Chengguan District of Lanzhou [2020-2-2-5]; Talent Innovation and Venture Project of Lanzhou City [2021-RC-125, 2020-RC-113]; Key R&D Program of Science and Technology Department of Gansu Province [20YF8FA116]; 2021 "Hundred Cities and Hundred Parks" Action Project of Lanzhou National High-tech Zone; Authorized Project of Lanzhou KejinTaiji Corporation, Ltd. [BMP-B-02-002]

作者

  • D

    Du, Tian-Qi (第一作者)

    chinese acad sci, inst modern phys · 1 · lanzhou univ

  • L

    Liu, Ruifeng

    univ chinese acad sci · chinese acad sci, inst modern phys

查看全部 7 位作者收起作者
  • Z

    Zhang, Qiuning (通讯)

    univ chinese acad sci · chinese acad sci, inst modern phys

  • L

    Luo, Hongtao

    univ chinese acad sci · chinese acad sci, inst modern phys

  • L

    Liu, Zhiqiang

    univ chinese acad sci · chinese acad sci, inst modern phys

  • S

    Sun, Shilong

    univ chinese acad sci · chinese acad sci, inst modern phys

  • W

    Wang, Xiaohu (通讯)

    univ chinese acad sci · chinese acad sci, inst modern phys · 1 · lanzhou univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417